Acepodia Appoints Nobel Laureate Dr. Carolyn Bertozzi to Its Board of Directors

ALAMEDA, Calif. & TAIPE, March 7, 2025 — Acepodia (6976: TT) today announced that Dr. Carolyn Bertozzi, Nobel Laureate in Chemistry, has been elected to the company’s Board of Directors through an Extraordinary Shareholders' Meeting. Dr. Bertozzi's appointment will further strengthen Acepodia's leadership in the fields of biochemistry, chemical biology, and innovative drug development.

Dr. Bertozzi is a pioneering scientist in the field of bioorthogonal chemistry and has made significant contributions to the application of this technology in cancer therapy, immunotherapy, and drug development. Her groundbreaking research has not only revolutionized academic understanding but has also paved the way for technological innovations in the biotech industry and clinical applications. Dr. Bertozzi previously served on the board of directors of Eli Lilly and Company from February 2017 to August 2021.

 “We are thrilled to welcome Dr. Carolyn Bertozzi to Acepodia’s Board of Directors following her election at the Extraordinary Shareholders' Meeting. Her expertise and influence in the scientific community will provide invaluable insights into our product pipeline and platform technologies, particularly in drug development and innovation.”, said Sonny Hsiao, Ph.D., Co-Founder, Chairman and CEO of Acepodia.

“I am honored to join Acepodia’s Board of Directors and to work alongside such a dynamic team to translate cutting-edge scientific research into therapies that have a real impact on patients. I am particularly impressed by Acepodia’s robust research and development capabilities in its conjugation technologies. The company’s innovative potential in these areas is poised to reshape the future of drug development and treatment. I look forward to contributing my expertise and knowledge to help guide the company forward,” commented Dr. Carolyn Bertozzi, Nobel Laureate. 

About Acepodia
Acepodia is transforming cancer and autoimmune disease treatment with first-in-class immune cell engagers that deliver enhanced and targeted potency through multiple conjugation platforms. Leveraging a family of bio-orthogonal click chemistry approaches originating from Nobel Prize laureate Carolyn Bertozzi’s lab, Acepodia’s platforms are designed to improve safety and offer broad applicability across hematologic and solid tumor cancers, as well as autoimmune diseases. By combining innovative science with a patient-centric vision, Acepodia aims to bring powerful, next-generation therapies to patients underserved by today’s treatments. For more information, please visit https://www.acepodia.com/.